Form 4: Processa Pharmaceuticals Insider Buys Shares
Insider Transaction Report
David Young, a Director and Officer at Processa Pharmaceuticals, Inc., acquired 2,067 shares of common stock.
Summary
- David Young, who holds the positions of Director and President of Research & Development at Processa Pharmaceuticals, Inc., has acquired 2,067 shares of the company's common stock.
- The transaction occurred on June 15, 2026, with shares purchased at a price of $2.22 per share.
- Following this acquisition, Mr. Young beneficially owns a total of 19,198 shares, with ownership structured directly and indirectly through various trusts and entities, including the Young-Plaisance Revocable Trust and CorLyst, LLC.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a moderately positive filing due to the insider purchase, which can signal confidence, but it lacks broader financial performance data.
Positives
- Insider buying activity, particularly by a Director and Officer, can signal confidence in the company's future prospects.
- The acquisition of 2,067 shares by David Young indicates a personal investment in the company's stock.
Future Outlook
This filing does not contain forward-looking statements or guidance.
Industry Context
StockSavvy.ai notes that insider buying, as reported in Form 4 filings, is a common indicator watched by investors across the pharmaceutical sector to gauge management's conviction in the company's valuation and future performance.
Stakeholder Impact
- Shareholders may view this insider purchase as a positive signal of management's confidence in the company's stock value.
Key Dates
| Date | Description |
|---|---|
| 06/15/2026 | Transaction Date for acquisition of common stock by David Young. |
| 06/16/2026 | Date of signature for the Form 4 filing. |
Recommendation
holdThe filing reports an insider purchase, which is generally a positive signal. However, without broader financial results or strategic updates, it's insufficient to warrant a strong buy or sell recommendation. A 'hold' reflects the neutral-to-positive sentiment derived solely from this insider transaction.
Keywords
Processa Pharmaceuticals, PCSA, Insider Trading, Form 4, Stock Acquisition, Beneficial Ownership, Director, Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.